CERO THERAPEUTICS HOLDINGS, INC. (CERO) Form 424B3 — Jun 26, 2026
Cero Therapeutics entered into an amended and restated promissory note with SRX Health Solutions for up to $1.4 million. The note carries a 10% interest rate and matures on May 28, 2027. The note is convertible into common stock at a price equal to the lower of $0.05 or 80% of the average of the five lowest trading prices in the 20 days prior to conversion. This structure provides significant downside protection for the lender but poses substantial dilution risk to existing shareholders.
Key figures
- Debt Amount
- $1,413,600
- Interest Rate
- 10%
- Maturity Date
- May 28, 2027
- Shares Offered
- 729,596,950
- Funded Amount
- $1,413,600
- Conversion Price Mechanism
- Lesser of $0.05 or 80% of average of 5 lowest trading prices in 20 days prior to conversion
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.